Gufic Biosciences Ltd.
Snapshot View

190.15 -3.70 ▼-1.9%

03 August 2021, 04:00:00 P.M.
Volume: 58,645

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.gufic.com
Financial Indicators
Market Cap 1,879.27 Cr.
Earnings per share (EPS) 4.56 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 42.49 Trailing Twelve Months Ending 2021-03
Industry PE 32.66 Trailing Twelve Months Ending 2021-03
Book Value / Share 17.89 Trailing Twelve Months Ending 2021-03
Price to Book Value 10.84 Calculated using Price: 193.85
Dividend Yield 0.05 Period Ending 2020-03
No. of Shares Subscribed 9.69 Cr. 96,944,506 Shares
FaceValue 1
Company Profile
Gufic Biosciences Ltd. started its plant biotechnology operation three years ago to produce and supply the high yielding and elite planting material of medicinal and other herbal plants using tissue culture techniques. The first biotechnology product was bixa, a source of natural food colour, for which the company has buy back arrangement with the farmers.

This company has a well developed tissue culture facility for production of 5 million plants per annum. The production unit is made by state of the art technology with six growth rooms, which can house 160000 culture bottles at a time. In the inoculation area, 30 persons can work in one shift. The air-conditioning and air handling system incorporates 5 micron and 0.5 micron filters and are designed for class 10,000 and class 100,000 as per us federal standards 209b. The work stations are however class 100.

The company has two green houses of 800 square meters with evaporative cooling, misting and shading equipment for hardening of tissue culture plants. 
In addition the company has shade houses for hardening of plants at 4 loacations.

With the expertise created in the field of agriculture, over the years, along with the right type of research, Gufic has entered into hybrid vegetable seeds. Gufic seeds deals in all major vegetable seeds namely, tomato, chilli, cabbage, cauliflower, capsicum, coriander, bhendi, bottle gourd, bitter gourd, ridge gourd, brinjal, cucumber and watermelon. It is bringing out varieties/hybrids as per the local demands and preferences for particular characteristics in a crop.

Towards this goal, Gufic seeds has already made arrangements with world class breeders and companies to get excellent seed material for development and promotions. Company commands the association of skilled, accomplished and seasoned professionals in research, production and marketing and we shall be striving to bring to you the best of hybrids and varieties to suit specific requirements on continues basis.

Business area of the company:

Gufic Biosciences Ltd. is engaged in diversified business viz. Pharma, Healthcare, Bio- Technology, Seeds, Herbal etc.

Gufic has entered into hybrid vegetable seeds. Gufic seeds deals in all major vegetable seeds namely, tomato, chilli, cabbage, cauliflower, capsicum, coriander, bhendi, bottle gourd, bitter gourd, ridge gourd, brinjal, cucumber and watermelon.

The company has developed in-house, on line real time computer software for forward planning of production schedule to meet market demands as well as monitoring daily production schedule and generating mis reports.


Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-1.91%
1 Week
+1.41%
1 Month
+5.14%
3 Month
+34.86%
6 Month
+51.39%
1 Year
+86.33%
2 Year
+244.79%
5 Year
+359.85%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 8.05 15.89 17.55 15.60 23.99 25.31 36.03 33.89 26.70
Return on Capital Employed (%) 15.02 18.44 17.45 18.38 24.24 24.26 34.10 29.65 22.67
Return on Assets (%) 2.20 4.04 4.25 3.49 5.24 5.52 8.04 8.04 6.52

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 20 22 26 27 34 37 54 75 96
Non Curr. Liab. 9 24 25 17 15 9 13 17 35
Curr. Liab. 47 44 60 84 104 128 169 218 260
Minority Int.
Equity & Liab. 75 90 111 127 152 175 235 310 391
Non Curr. Assets 24 39 42 36 33 31 37 46 92
Curr. Assets 51 50 69 91 120 143 198 264 299
Misc. Exp. not W/O
Total Assets 75 90 111 127 152 175 235 310 391

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 84 100 123 152 202 246 306 351 358
Other Income 0 0 1 1 1 1 3 4 7
Total Income 84 101 124 152 203 247 308 355 365
Total Expenditure -76 -89 -111 -137 -183 -223 -267 -305 -313
PBIDT 8 11 13 15 20 24 42 50 51
Interest -3 -4 -4 -4 -6 -6 -9 -10 -13
Depreciation -2 -2 -2 -4 -4 -4 -4 -5 -8
Taxation -1 -2 -2 -2 -3 -5 -13 -13 -7
Exceptional Items 2
PAT 2 3 4 4 7 9 16 22 23

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 5 5 11 11 -4 -4 -5 5 46
Cash Fr. Inv. -3 -13 -3 -2 -1 -5 -9 -13 -42
Cash Fr. Finan. -2 8 -7 -5 5 7 14 8 -3
Net Change 0 0 1 4 0 -1 1 0 1
Cash & Cash Eqvt 1 1 3 6 6 3 4 4 4

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 65.75 65.75 65.75 65.75 65.75 65.75 65.75 65.75 65.13
Public 34.25 34.25 34.25 34.25 34.25 34.25 34.25 34.25 34.87
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Tue, 20 Jul 2021
Shareholding for the Period Ended June 30 2021
Gufic Biosciences Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here
Mon, 12 Jul 2021
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 please find enclosed herewith the letter received from our Registrar and Share Transfer Agent M/s Link Intime India Private Limited for the quarter ended June 30 2021.
Mon, 12 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0000
Name of the Signatory :- Ami N Shah
Designation :- Company Secretary and Compliance Officer

Technical Scans View Details

Mon, 02 Aug 2021
Higher Delivery Quantity Higher Delivery Quantity
Higher Trade Quantity Higher Trade Quantity
Higher Trade and Delivery Quantity Higher Trade and Delivery Quantity
Close Crossing Last Week High Close Crossing Last Week High
Close Crossing Last Month Close From Below Close Crossing Last Month Close From Below

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 185,816.50 794.85 +2.6%
Divi's Laboratories Ltd. 130,822.92 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. 78,219.21 4,721.20 +0.4%
Cipla Ltd. 74,356.30 927.25 +0.6%
Cadila Healthcare Ltd. 60,574.85 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. 58,218.41 4,076.05 +0.7%
Piramal Enterprises Ltd. 56,317.82 2,507.65 +0.7%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 30.95 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2021-03 65.93 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.02 4,721.20 +0.4%
Cipla Ltd. Consolidated 2021-03 30.92 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 28.39 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 387.19 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 42.27 2,507.65 +0.7%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 3.88 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2021-03 14.08 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.37 4,721.20 +0.4%
Cipla Ltd. Consolidated 2021-03 4.06 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 4.66 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.67 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 1.65 2,507.65 +0.7%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,721.20 +0.4%
Cipla Ltd. Consolidated 2020-03 0.18 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 2,507.65 +0.7%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,721.20 +0.4%
Cipla Ltd. Consolidated 2020-03 10.09 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 2,507.65 +0.7%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,721.20 +0.4%
Cipla Ltd. Consolidated 2020-03 12.53 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 10.03 2,507.65 +0.7%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,721.20 +0.4%
Cipla Ltd. Consolidated 2020-03 17,131.99 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 2,507.65 +0.7%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,721.20 +0.4%
Cipla Ltd. Consolidated 2020-03 1,546.98 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 2,507.65 +0.7%